Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of subcutaneous amivantamab (co-formulated with rHuPH20) in advanced or metastatic solid tumors including EGFR-mutated non-small cell lung cancer
2022-000526-21Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of amivantamab in EGFR-mutated non-small cell lung cancer and Nonhematologic neoplasms (4 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Objective Response Rate (ORR) and Safety (Cohort 4). Started Sep 2022; status: active.
02
Drugs
amivantamab
03
Conditions
EGFR-mutated non-small cell lung cancerNonhematologic neoplasms
Beyond the preview
Go deeper on 2022-000526-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000526-21.